Is this you? Create Your Porfile

A. Haque

University of Texas Health Science Center at San Antonio

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where A. Haque is active.

Explore More

Publication

Featured researches published by A. Haque.

Journal of Clinical Oncology | 2010

Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

Andreas Hochhaus; G. Saglio; H. Kantarjian; A. Haque; Yaping Shou; Richard C. Woodman; Timothy P. Hughes; Jerald P. Radich; Giovanni Martinelli; Dong Hwan Dennis Kim

6516 Background: BCR-ABL transcript levels have been reported to be a predictor of response outcomes, including the detection of new mutations, in pts with imatinib resistance. In this posthoc anal...

Blood | 2008

Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.

Hagop M Kantarjian; Francis J. Giles; Kapil N. Bhalla; Richard A. Larson; Norbert Gattermann; O. Ottmann; A. Haque; Neil J. Gallagher; Michele Baccarani; Philipp D. le Coutre

Blood | 2008

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

Philipp D. le Coutre; Francis J. Giles; Andreas Hochhaus; Jane F. Apperley; Gert Ossenkoppele; A. Haque; Neil J. Gallagher; Michele Baccarani; Jorge Cortes; Hagop M Kantarjian

Journal of Clinical Oncology | 2008

Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib

Frank Giles; Richard A. Larson; H. Kantarjian; P. le Coutre; Francesca Palandri; A. Haque; Neil Gallagher; O. Ottmann

Journal of Clinical Oncology | 2008

Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)

Elias Jabbour; Andreas Hochhaus; P. le Coutre; Giovanni Rosti; Kapil N. Bhalla; A. Haque; Neil Gallagher; Frank Giles; J. Cortes; H. Kantarjian

Journal of Clinical Oncology | 2008

Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study

P. le Coutre; Frank Giles; Jane F. Apperley; O. Ottmann; Richard A. Larson; A. Haque; Neil Gallagher; Giovanni Rosti; J. Cortes; H. Kantarjian

Journal of Clinical Oncology | 2007

A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)

Giovanni Rosti; P. le Coutre; Kapil N. Bhalla; Frank Giles; Gert J. Ossenkoppele; Andreas Hochhaus; Norbert Gattermann; A. Haque; A. Weitzman; M. Baccarani; H. Kantarjian

Blood | 2008

Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)

Elias Jabbour; Hagop M Kantarjian; Michele Baccarani; Philipp D. le Coutre; A. Haque; Neil J. Gallagher; Jorge Cortes; Francis J. Giles

Journal of Clinical Oncology | 2009

Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study

P. le Coutre; Frank Giles; Andreas Hochhaus; Jane F. Apperley; Gert J. Ossenkoppele; A. Haque; Neil Gallagher; M. Baccarani; J. Cortes; H. Kantarjian

Blood | 2007

Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.

Timothy P. Hughes; Giuseppe Saglio; Giovanni Martinelli; Dong-Wook Kim; Simona Soverini; Martin C. Mueller; A. Haque; Neil Gallagher; Yaping Shou; Jerald P. Radich; Susan Branford; Andreas Hochhaus

Explore More